ASH 2023 | Risk-factors for Richter’s transformation
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, briefly outlines the risk factors for Richter’s transformation (RT), including complex karyotype, TP53 abberation, the metabolism in chronic lymphocytic leukemia (CLL) cells, as well as the tumor microenvironment and T-cell function. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Barbara Eichhorst 03
So, there were yesterday a couple of interesting abstracts on translational research and development of Richter’s transformation. So we learned that probably the primary genetics of CLL, we know that patients with complex carrier type TP53 abberation have a higher risk of developing Richter’s transformation...
Barbara Eichhorst 03
So, there were yesterday a couple of interesting abstracts on translational research and development of Richter’s transformation. So we learned that probably the primary genetics of CLL, we know that patients with complex carrier type TP53 abberation have a higher risk of developing Richter’s transformation. We also learned that probably the metabolism in the CLL cells plays a role as well as the microenvironment, probably also T-cell function. And patients who develop Richter’s transformation, the prognostic parameters we do have here are the old known prognostic parameters- it’s age, it’s a poor ECOG status. And in our study with the tislelizumab plus zanubrutinib combination, we have also seen that patients have really heavy severe B symptoms; they also did worse with this targeted therapy.
Read more...
Disclosures
Consultancy: AstraZeneca, BeiGene, Gilead, Janssen, Lilly, MSD, Abbvie
Honoraria: AstraZeneca, BeiGene, MSD, F. Hoffmann-La Roche Ltd, Abbvie
Research Funding: AstraZeneca, BeiGene, Gilead, Janssen, F. Hoffmann-La Roche Ltd, Abbvie
Speakers Bureau:AstraZeneca, BeiGene, Janssen, Lilly, MSD, F. Hoffmann-La Roche Ltd, Abbvie
